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ABSTRACT
Oncolytic adenoviruses with restricted replication can be produced if the expression of crucial transcription
units of the virus is controlled by tissue- or tumor-specific promoters. Here we describe a method for the rapid
incorporation of exogenous promoters into the E1A and E4 regions of the human adenovirus type 5 genome.
Using this system, we have generated AdEHT2 and AdEHE2F, two conditionally replicative adenoviruses for
the treatment of breast cancer. The expression of the E1A gene in both viruses is controlled by a minimal
dual-specificity promoter that responds to estrogens and hypoxia. The tight regulation of E1A expression cor-
related with the ability of these viruses to replicate and kill human cancer cells that express estrogen recep-
tors, or are maintained under hypoxic conditions. The telomerase reverse transcriptase (TERT) promoter and
the E2F-1 promoter are preferentially activated in cancer cells. They were introduced into the E4 region of
AdEHT2 and AdEHE2F, respectively. The telomerase core promoter failed to block the replication of the
virus in telomerase-negative cells. In contrast, AdEHE2F was attenuated in nontransformed quiescent cells
growing under normoxic conditions, suggesting that an intact pRB pathway with low levels of E2F tran-
scription factors acts as a negative modulator for the virus. These data indicate that the simultaneous regu-
lation of E1A and E4 viral transcription units by the appropriate combination of promoters can increase the
tumor selectivity of oncolytic adenoviruses.
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OVERVIEW SUMMARY
The lytic cycle of adenovirus leads to the death of the in-
fected cells and the liberation of thousands of new viral par-
ticles. These properties can be exploited for the generation
of therapeutic agents against cancer, if the replication of the
virus is redirected to the malignant tissues. Three common
characteristics found in most solid tumors are the existence
of hypoxic areas, the expression of telomerase in the cells,
and the elevation in free E2F transcription factors due to
alterations in the pRB pathway. We have tested a combi-
nation of promoters that are activated under these circum-
stances in order to control the expression of regulatory pro-
teins of adenovirus. We found that control of the viral E1A
region by a hypoxia-responsive promoter and, to a lesser
extent, control of the E4 region by an E2F-responsive pro-
moter allow preferential replication of adenovirus in solid
tumors.
INTRODUCTION
THE NEW GENERATION of conditionally replicative aden-oviruses (CRADs) represents an advance over the previous
replication-deficient vectors used in gene therapy against can-
cer. The ability to replicate their genome after infection allows
them to amplify the effect that an initial load of vector may
have. More importantly, they are therapeutic agents by them-
selves because they retain the ability to kill the cells as the last
step of their lytic cycle (Alemany et al., 2000). There are two
major approaches to achieve preferential replication of adeno-
virus in cancer cells (Kruyt and Curiel, 2002). The so-called
type 1 CRADs are based on the deletion or functional disrup-
tion of viral genes that activate the cell cycle in the infected
cell, an effect that is needed for replication of the viral genome.
This idea led to the development of dl1520, the first and most
extensively used oncolytic adenovirus (Kirn, 2001; Biederer et
al., 2002). It contains a deletion in the E1B-55 kDa gene, which
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is essential for the virus to inactivate p53 and force the infected
cell to enter the S phase of the cell cycle (Bischoff et al., 1996).
As a result, dl1520 shows preferential replication in those cells
that have the p53 and related pathways already compromised
by different mechanisms (Ries et al., 2000; Yang et al., 2001),
as is the case in the majority of cancer cells. In accordance with
the same principle, an adenovirus with a small deletion in the
E1A gene targets cells with defects in the pRB pathway (Fueyo
et al., 2000; Heise et al., 2000). However, these viruses are of-
ten attenuated even in the target cells, because the deletions can
affect other functions of these viral genes. More recently, an
alternative method to achieve tumor specificity has been de-
scribed (Ramachandra et al., 2001). The authors constructed a
replication-competent adenovirus that expresses a repressor of
E2F activity under the control of a promoter that responds to
p53.
The second strategy to develop CRADs is based on the tran-
scriptional control of genes that are necessary for replication of
the virus. The viral genes are not modified; rather, they are
placed under the control of promoters that are preferentially ac-
tive in the tumor cells, compared with the surrounding tissues.
E1A and E4 are the first two transcriptional units to be acti-
vated after infection, and both are required for efficient repli-
cation and viral production (Falgout and Ketner, 1987). The
control of the E1A region is especially important because E1A
acts as a strong activator for most of the transcription units in
the adenovirus genome (Shenk, 1996). This means that if E1A
is not expressed, not only is the virus unable to replicate, but
also the expression of other viral proteins is greatly attenuated.
The E4 region encodes a group of proteins that perform diverse
functions and show a complex repertoire of interactions with
other viral and cellular proteins (Tauber and Dobner, 2001).
They are involved in replication of viral DNA, particle assem-
bly, and interference with functions of the host cell such as com-
petition for protein synthesis and induction of apoptosis (Hal-
bert et al., 1985; Branton and Roopchand, 2001). This latter
effect can be important for an adequate release of virions once
the viral DNA has been encapsidated. Therefore, controlling si-
multaneously the expression of E1A and E4 genes achieves a
tighter control over replication of the virus (Hernandez-Alco-
ceba et al., 2000; Fuerer and Iggo, 2002), and at the same time
it decreases the risk of recombination and reversion to the wild-
type genome. Promoters that have been used to control the E1A
region include the prostate-specific promoter and enhancer for
prostate cancer (Yu et al., 1999), the osteocalcin promoter for
bone metastases (Matsubara et al., 2001), the midkine promoter
for Ewing’s sarcoma and neuroblastoma (Adachi et al., 2001),
the a-fetoprotein promoter for hepatocellular carcinomas (Hal-
lenbeck et al., 1999), the surfactant protein B (SPB) promoter
for lung cancer (Doronin et al., 2001), and promoters contain-
ing tcf/LEF transcription factor-binding sites for colon cancer
(Fuerer and Iggo, 2002). These CRADs showed preferential
replication in cancer cells, and demonstrated antitumor activity
in preclinical models. However, for many human malignancies,
including breast cancer, a tumor-specific promoter has not yet
been characterized in detail. A CRAD utilizing the MUC-1 pro-
moter in the E1A region has been made because this protein is
overexpressed in many mammary tumors (Kurihara et al.,
2000), but some normal tissues also express this protein (Brug-
ger et al., 1999). In an initial approach to develop a CRAD for
breast cancer, we constructed AdERE2 (Hernandez-Alcoceba
et al., 2000), a recombinant adenovirus that has both the E1A
and E4 promoters deleted and substituted by a portion of the
pS2 promoter containing two estrogen response elements
(EREs). The estrogen receptor (ER) binds to these sequences
and exerts its function as a transcriptional activator (Ekena et
al., 1998). This means that estrogens can activate the promoter
only in cells that express ERs, which is the case in up to 70%
of human breast cancers (Valavaara, 1997). In AdERE2, both
E1A and E4 were efficiently controlled by this promoter, and
we showed preferential replication and killing of breast cancer
cells expressing ERs. In addition, AdERE2 was able to com-
plement in trans the E1A deficiency of a replication-defective
adenovirus vector expressing the proapoptotic gene encoding
Bcl-xs.
One of the advantages of using transcriptional control for the
generation of CRADs is the possibility of combining different
response elements in the same regulatory unit to create artifi-
cial multispecificity promoters. In addition, different transcrip-
tion units can be separately regulated in the same virus. In this
way, the virus can be activated by a combination of stimuli that
resemble the conditions present in tumor tissues. Because of
the complexity of the adenovirus genome, the performance of
these combinations of promoters can be tested only when the
actual virus is produced. To facilitate this process, we have en-
gineered a plasmid that contains the adenovirus genome with
unique restriction sites flanking the E1A and E4 promoter re-
gions. We have used this backbone to produce the CRADs that
we describe here.
One common characteristic of most solid tumors is that they
grow in an environment of low oxygen tension (hypoxia), due
to the their aberrant vasculature (Zhong et al., 1999; Talks et
al., 2000). Virtually all the cells in an organism have mecha-
nisms for sensing and responding to lack of oxygen and nutri-
ents. The transcription factor HIF (hypoxia-inducible factor) is
an a/b heterodimer. The a subunit of this transcription factor
is rapidly ubiquitinated and degraded by the proteasome under
normoxic conditions, but the protein is stabilized in hypoxic en-
vironments (Huang et al., 1998). The high levels of HIF induce
the expression of a repertoire of genes necessary for adaptation
to low oxygen. HIF binds to a sequence in the promoter of these
genes, named the hypoxia responsive element (HRE). The use
of this sequence as an enhancer for the expression of thera-
peutic genes has been proposed for the treatment of solid tu-
mors (Dachs et al., 1997). We have already described the char-
acterization of a hybrid promoter containing HREs and EREs
to control the expression of the proapoptotic gene harakiri (Hrk)
(Hernandez-Alcoceba et al., 2001). This therapeutic cassette
was evaluated with a replication-deficient adenovirus, and we
showed specific induction of apoptosis in ER1 breast cancer
cells, or in any other cell growing under hypoxic conditions. In
the present study, we have used a minimal artificial promoter
containing EREs and HREs to control the expression of E1A
in two different CRADs, AdEHT2 and AdEHE2F. We placed
the E4 region of these viruses under the control of two differ-
ent promoters that have shown great potential for cancer tar-
geting. In AdEHT2, this transcription unit is controlled by the
core human telomerase reverse transcriptase (hTERT) pro-
moter. Telomerase is a ribonucleotide complex composed of an
RNA template (hTR) and a catalytic protein subunit with re-
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verse transcriptase activity (hTERT) (Meyerson et al., 1997).
This enzyme is necessary to maintain the ends of the chromo-
somes (telomeres), which cannot be replicated by DNA poly-
merase. Telomerase adds the hexameric sequence TTAGGG,
preventing the shortening and destabilization of the chromo-
somes after multiple rounds of cell division (Greider, 1996). In-
terestingly, telomerase activity is not detected in most human
somatic cells, but, in contrast, the expression of hTERT is re-
activated in most human cancers, as well as germ line cells and
probably stem cells (Harle-Bachor and Boukamp, 1996; Ulaner
et al., 1998). The hTERT promoter has been characterized by
different groups (Horikawa et al., 1999; Takakura et al., 1999;
Wick et al., 1999), and it has already been used to selectively
direct the expression of proteins to cancer cells (Komata et al.,
2001; Majumdar et al., 2001). Because both E1A and E4 are
necessary for efficient viral replication, we hypothesized that
having this promoter in the E4 region could add a second level
of tumor specificity to the virus.
In the case of AdEHE2F, we placed the E4 region of the
virus under the control of the E2F-1 promoter. E2F-1 belongs
to a family of transcription factors that are functionally active
in the G1/S transition of the cell cycle. They bind to specific
sites in the promoters of genes that are required for entry into
the S phase (Polager et al., 2002). Interestingly, the E2F-1 pro-
moter itself contains E2F-binding sites (Johnson et al., 1994).
In quiescent cells, E2F factors are rendered inactive by bind-
ing to pRB and related proteins. In addition to this sequestra-
tion, the E2F–pRB complexes act as transcription repressors on
the E2F sites (Sellers et al., 1995). On the other hand, in trans-
formed cells the pRB pathway is commonly altered, and there-
fore E2F activity is constantly elevated. Identification of the
E2F-1 promoter (Hsiao et al., 1994; Neuman et al., 1994) of-
fered the possibility of using it for transcriptional targeting of
tumors (Parr et al., 1997). It is important to mention that viral
protein E1A can disrupt E2F–pRB complexes and therefore ac-
tivate the E2F-1 promoter (Flint and Shenk, 1997). This means
that the alteration in the pRB pathway might not be a require-
ment for replication of AdEHE2F if the promoter controlling
the E1A region is already activated. However, in most normal
tissues, the absence of ERs and the low levels of HIF and E2F
activity should keep both E1A and E4 transcription units inac-
tive (Fig. 1). In summary, we found both AdEHT2 and
AdEHE2F viruses to be fully active in ER1 cancer cells, or in
cells growing under hypoxic conditions, in good correlation
with the expression of the E1A region. Regarding the E4 re-
gion, we were unable to demonstrate restriction of AdEHT2 vi-
ral replication in telomerase-negative cells. On the other hand,
we observed attenuation of AdEHE2F replication in normal qui-
escent cells, which suggests that the E2F-1 promoter retains its
specificity in the context of the adenovirus genome.
MATERIALS AND METHODS
Cell lines
MCF7 (ATCC HTB 22) and BT-474 (ATTC HTB 20) are
ER1 human breast cancer cell lines. SK-BR-3 (ATCC HTB 30)
is an ER2 human breast cancer cell line. Cells were maintained
in RPMI medium (BioWhittaker, Walkersville, MD) supple-
mented with 10% fetal bovine serum (FBS) (HyClone, Logan,
UT). For MCF7 and BT-474, insulin (10 mg/ml; GIBCO-BRL,
Grand Island, NY) was added. HeLa (ATCC CCL 2) is an ER2
human cervical cancer cell line, and it was maintained in Dul-
becco’s modified Eagle’s medium (DMEM; GIBCO-BRL)
supplemented with 10% FBS. IMR-90 (ATCC CCL 186) and
BJ (ATCC CRL-2522) are human primary fibroblasts from lung
and skin, respectively. They were maintained in Eagle’s mini-
mal essential medium (EMEM; BioWhittaker), supplemented
with 10% FBS, 0.1 mM nonessential amino acids, and sodium
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FIG. 1. Proposed mechanism for the preferential replication of AdEHT2 and AdEHE2F in solid tumors. On the left, some gen-
eral characteristics of solid tumors are listed, and their influence on the replication of viruses is indicated with arrows. The E1A
and E4 transcription units of adenovirus are represented as solid and open boxes, respectively. A hypoxic environment and the
expression of estrogen receptors in the cells can independently activate the E1A unit of both viruses. The E4 unit of AdEHT2 is
supposed to be activated in cells that express telomerase, and therefore it might attenuate the replication of the virus in telomer-
ase-negative cells (see text). The E4 unit of AdEHE2F should be activated in cells that show alterations in the pRB pathway, be-
cause the levels of free E2F transcription factors are elevated in these cells. Because the viral E1A protein can produce the same
effect, hypoxia and estrogens in ER1 cells can indirectly activate the E4 unit of AdEHE2F. The expression of E1A and E4 units
would allow adenoviral replication, destruction of the cells, and propagation of the infection within the tumor.
bicarbonate (1.5 g/liter) (GIBCO-BRL). NHFib cells are also
human skin fibroblasts, and were maintained in DMEM sup-
plemented with 10% FBS. Human dermal microvascular endo-
thelial cells (HDMECs) were maintained in EBM-2 medium
supplemented with EGM-2-MV (endothelial microvascular cell
growth medium 2) additives (Clonetics, Walkersville, MD).
NHK cells are normal human keratinocytes from skin. They
were maintained in medium 154CF supplemented with HKGS
(Cascade Biologics, Portland, OR). When the experiment re-
quired depletion of estrogens, IMEM without phenol red was
used (GIBCO-BRL), supplemented with 2.5% charcoal–dex-
tran-stripped serum (HyClone). Estradiol (17b-estradiol) and 4-
OH-tamoxifen were purchased from Sigma (St. Louis, MO).
A549 (ATCC CCL 185) is a human lung cancer cell line. It
was maintained in Ham’s F12 (BioWhittaker) supplemented
with 10% FBS. 293E4pIX cells (Microbix, Toronto, ON,
Canada) are a 293 cell line transformed with the adenovirus
type 5 E4 transcription unit driven by the dexamethasone-in-
ducible mouse mammary tumor virus (MMTV) promoter, and
the protein IX unit driven by the ZnCl2-inducible metalloth-
ionein promoter. It was maintained in EMEM supplemented
with 10% heat-inactivated FBS. The expression of the E4 unit
was induced by adding 1 mM dexamethasone (Gensia, Irvine,
CA) to the culture medium. All culture media were supple-
mented with penicillin (100 U/ml), streptomycin (100 U/ml),
and amphotericin B (Fungizone, 0.25 mg/ml; BioWhittaker).
Construction and characterization 
of reporter plasmids
The pB5XEH3 plasmid was constructed as follows. A cas-
sette containing five copies of the ERE (GGTCACAGTGACC)
plus a TATA box were subcloned into the polycloning site of
the pGL2-Basic luciferase reporter plasmid (Promega, Madi-
son, WI). Three copies of the HRE consensus element of the
mouse phosphoglycerate kinase 1 (PGK-1) 59 enhancer (TGT-
CACGTCCTGCACGAC) were then subcloned upstream of the
ERE sequences, using the SmaI site. To verify the response to
estrogens, the plasmid was transfected into MCF7 cells, using
the FuGENE 6 reagent, as described by the manufacturer
(Roche, Indianapolis, IN). The cells (typically 7.5 3 104/well
in a 12-well plate) were incubated for 8 hr in estrogen-free
medium and then transfected with 0.5 mg of the reporter plas-
mid and 0.1 mg of the plasmid pRLTK (Promega) in order to
quantify the efficiency of transfection. Six hours later, the trans-
fection medium was removed and new medium was added con-
taining the indicated treatments. After 14–18 hr, cells were
lysed and analyzed for luciferase activity, using the dual lucif-
erase reporter assay system (Promega) as indicated by the man-
ufacturer. The specific luciferase activity measured in a lumi-
nometer is presented as (firefly/Renilla) 3 1000 luciferase
units.
Construction of AdEHT2 and AdEHE2F
Using the plasmid pShutAd (Hernandez-Alcoceba et al.,
2000), we used standard molecular biology methods to produce
a plasmid containing the E1A and E4 promoters flanked by
unique restriction sites. The E1A promoter region (bp 341 to
499) was flanked by BstBI sites. The E4 promoter region (bp
35619 to 35818) was flanked by I-CeuI and SwaI sites, as shown
in Fig. 2A. An insulator sequence (bovine growth hormone tran-
scription stop signal) was subcloned upstream of the E1A pro-
moter. The insulator was obtained from the pcDNA3 plasmid
(Invitrogen, Carlsbad, CA) by digestion with PvuII and NotI
(Vassaux et al., 1999). The core hTERT promoter (bp 2208 to
176) and the E2F-1 promoter (bp 2218 to 151) were ampli-
fied from genomic DNA with the Advantage-GC genomic PCR
kit (Clontech, Palo Alto, CA). The primers used were 59-TACT-
GTAACTATAACGGTCCTAAGGTAGCGACCAGTG-
GATTCGCGGGCACAG-3 9 and 59-TAAGTATTTAAATCG-
CGGGGGTGGCCGGGGCCAGGGCTTC-3 9 for the hTERT
promoter, and 59-TACTGTAACTATAACGGTCCTAAGGT-
AGCGTGGTACCATCCGGACAAAGCC-3 9 and 59-TAAG-
TATTTAAATGGCGAGGGCTCGATCCCGC-3 9 for the E2F-
1 promoter. The plasmids containing the modified adenovirus
genome were named pSEHT2 and pSEHE2F, respectively. For
the production of viral particles, these plasmids were digested
with PacI, phenol–chloroform extracted and ethanol precipi-
tated, and then transfected into 293E4pIX cells by the calcium
phosphate method. The cells were treated with 1 mM dexam-
ethasone until cytopathic effect (CPE) was observed. Individ-
ual plaques were isolated as described (Hernandez-Alcoceba et
al., 2000). Modifications in the E1A and E4 promoter regions
were verified by polymerase chain reaction (PCR) using spe-
cific primers. The viruses were amplified in A549 cells, puri-
fied on CsCl gradients, and desalted in G-50 Sephadex columns.
Titration was done according to the plaque-forming assay
method. The titer was 1.1 3 107 and 0.7 3 107 PFU/ml for
AdEHE2F and AdEHT2, respectively.
Analysis of transcriptional activation of 
E1A and E4 units
To analyze the responsiveness of the ERE/HRE promoter in
the context of the adenoviral genome, we performed Northern
blot assays of cells infected with AdEHT2 and AdEHE2F.
Wild-type adenovirus type 5 (AdWT) was used as a control.
Cells (5 3 106 cells/100-mm plate) were pretreated for 10 or
14 hr under the indicated conditions of estrogens and/or hy-
poxia. Infection was performed for 1 hr in 3 ml of culture
medium with a multiplicity of infection (MOI) of 20 PFU/cell.
The infection medium was then removed and the cells were in-
cubated for 10 hr under the same conditions. Total RNA was
extracted with TRIzol reagent (GIBCO-BRL), and 30 mg of
RNA was formaldehyde–formamide denatured, fractionated in
a 1.2% agarose gel, and transferred to a nylon membrane (Hy-
bond-N1; Amersham, Buckinghamshire, UK). The E1A probe
consisted of the 998-bp SspI–XbaI fragment from the adenovi-
ral genome (nucleotides 341 to 1339), and the E4 probe was
the 800-bp SspI–AsnI fragment (nucleotides 34634 to 35419).
They were radiolabeled with a random primed DNA labeling
kit (Roche). The membrane was prehybridized for 2 hr at 68°C
in ExpressHyb hybridization solution (Clontech) in the pres-
ence of salmon sperm DNA (1 mg/ml) and tRNA (1 mg/ml).
Hybridization was at 68°C for 1 hr with 2 3 106 cpm/ml of the
probe. The membrane was then washed with 23 SSC, 0.1%
sodium dodecyl sulfate (SDS) at room temperature for 20 min,
and twice with 0.13 SSC, 0.1% SDS at 50°C (13 SSC is 0.15
M NaCl and 15 mM sodium citrate, pH 7.0). Finally, it was au-
toradiographed. To confirm homogeneous RNA loading and hy-
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bridization, we hybridized the same membranes with a human
b-actin probe.
Cytopathic effect and viability of cells
After infection of cells with the different viruses, the ap-
pearance of cytopathic effect (rounding and detachment) was
monitored and cells were photographed with a digital camera
(Pixera, Los Gatos, CA), typically 9 days after infection (data
not shown). To quantify the viability of cells, the MTT assay
was used (Sigma). At the time of analysis, cells were washed
with 1 ml of phosphate-buffered saline (PBS) and 300 ml of a
solution containing thiazolyl blue (MTT) solution (0.8 mg/ml)
was added to the cells. Five hours later, 300 ml of solubiliza-
tion solution (20% [w/v] SDS in 50% [v/v] N,N-dimethylfor-
mamide) were added, and 12 hr later the absorbance at 600 nm
was read in a spectrophotometer. The significance of the dif-
ferences observed was analyzed by t test.
In vivo assays in nude mice
The antitumor effect of AdEHT2 and AdEHE2F was tested
in human tumor xenografts implanted in 5- to 7-week-old Hsd
nu/nu mice (Harlan, Indianapolis, IN). Estradiol pellets (0.72
mg of 17b-estradiol, 60-day release; Innovative Research of
America, Sarasota, FL) were implanted subcutaneously in the
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FIG. 2. Construction of AdEHT2 and AdEHE2F. (A) Method for the production of adenoviruses with modifications in the E1A
and E4 promoters. These regions were flanked by unique restriction sites (BstBI for E1A and SwaI/I-CeuI for E4) in a plasmid
that contains the entire adenovirus type 5 genome. After subcloning the exogenous promoters, the plasmids obtained (pSEHT2
and pSEHE2F in this case) are digested with PacI in order to liberate the viral genome, and they are transfected in permissive
cells to generate the CRADs AdEHT2 and AdEHE2F, respectively. Kan, Kanamycin resistance; Ori, origin of replication for E.
coli; Ins, insulator sequence. (B) Schematic representation of the modifications introduced in the viral genome. An insulator se-
quence was placed between the overlapping E1A enhancer/packaging signals and the E1A promoter. The wild-type E1A pro-
moter was substituted with an artificial minimal promoter containing three hypoxia responsive elements (HREs) and five estro-
gen response elements (EREs). The E4 promoter was substituted with the hTERT and E2F-1 promoters in AdEHT2 and AdEHE2F,
respectively. ITR, Inverted terminal repeats; c.s., coding sequence.
mice. Two days later, 15 3 106 BT-474 cells were resuspended
in serum-free RPMI plus 80% Matrigel (Collaborative Bio-
medical Products, Bedford, MA) and injected subcutaneously
into the second left breast. When tumors reached an average
volume of approximately 200 mm3, viruses were diluted to 5 3
108 PFU in 100 ml of PBS and injected intratumorally. Tumor
volume was measured weekly and calculated according to the
equation (D 3 d 2 )/2, where D and d are the major and minor
diameters, respectively. The significance of the differences ob-
served was analyzed by t test.
The toxicity assays were performed in Hsd nu/1 mice by in-
travenous injection of 100-ml virus solutions in PBS via the
retro-orbital plexus. Mice were monitored daily for signs of
mortality and morbidity. Two days after viral injection, blood
samples were collected and levels of the hepatic enzyme ala-
nine aminotransferase (ALT) were analyzed in order to assess
liver toxicity.
RESULTS
Construction of AdEHT2 and AdEHE2F
To test different combinations of promoters in the E1A and
E4 transcription units of adenovirus, we constructed a plasmid
containing the adenovirus type 5 genome with these regions
flanked by unique restriction sites (Fig. 2A), as suggested by
Mizuguchi and Kay (1998). In the E4 region, we subcloned the
hTERT promoter (virus AdEHT2) or the E2F-1 promoter (virus
AdEHE2F), as indicated in Fig. 2B. These promoters have al-
ready been described by other groups (Hsiao et al., 1994; Neu-
man et al., 1994; Horikawa et al., 1999; Takakura et al., 1999;
Wick et al., 1999). The control of the E1A region is crucial for
the regulation of CRADs. The wild-type virus contains a strong
enhancer for E1A that overlaps with the packaging signal. To
prevent any possible interference with the function of the ex-
ogenous promoter used in this area, we introduced an insulator
sequence (bovine growth hormone transcription stop signal) 
between this enhancer and the location of the E1A promoter.
In an effort to minimize the basal activity of the promoter, we
constructed and characterized a new minimal promoter con-
taining three HREs and five EREs plus a TATA box. A lucif-
erase reporter was used to test its activation by estrogens and
hypoxia (Fig. 3). The ER1 human breast cancer cell line MCF7
was transiently transfected with this plasmid and the cells were
exposed to estrogens (2.5 nM 17b-estradiol), hypoxia (1% O2),
or both stimuli together. The result shows that this promoter has
low basal activity in the absence of estrogens (Fig. 3A). As de-
scribed previously for a similar promoter, both estrogens and
hypoxia stimulated transcription, which means that the HRE and
ERE sites can work independently. However, in the case of this
artificial promoter the response to estrogens (25-fold over the
untreated cells) was lower than that obtained with hypoxia (80-
fold). The addition of the estrogenic competitive inhibitor 4-OH-
tamoxifen partially blocked the response to estrogens, indicat-
ing that the induction is specific (Fig. 3A). In ER- HeLa cells,
no elevation of the luciferase activity was observed, whereas hy-
poxia was still able to stimulate transcription (Fig. 3B). In sum-
mary, the ERE/HRE minimal promoter combined low basal ac-
tivity with good inducibility. Its reduced size and the lack of
potentially undesirable response elements make it a good can-
didate for substitution of adenoviral regulatory sequences. We
then introduced it in the adenovirus genome, replacing the wild-
type E1A promoter in both AdEHT2 and AdEHE2F (Fig. 2B).
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FIG. 3. Characterization of the ERE/HRE minimal promoter. The pB5XEH3 luciferase reporter plasmid containing this pro-
moter was transfected into MCF7 cells (A) or HeLa cells (B) that had been estrogen deprived for 8 hr. The constitutive Renilla
luciferase reporter pRLTK was cotransfected in order to control the efficiency of transfection. Six hours later, the transfection
medium was removed and new medium containing the indicated treatments was added. After 16 hr, the cells were lysed and an-
alyzed for luciferase activity. The columns represent the equation (firefly/Renilla) luciferase units 3 103. Note that the y axis
range is different in each panel. C, Untreated; E, 2.5 nM 17b-estradiol; ET, 2.5 nM 17b-estradiol plus 2.5 mM 4-OH-tamoxifen;
H, hypoxia (1% O2); EH, 2.5 nM 17b-estradiol plus hypoxia. The experiment was repeated five times for MCF7 cells and two
times for HeLa cells, with similar results.
The viral particles were produced by transfection of the respec-
tive plasmids, as described in Materials and Methods.
Transcriptional control of the E1A and E4 regions
Once the AdEHT2 and AdEHE2F viruses were produced,
we investigated whether the exogenous promoters were able to
control the expression of E1A and E4 in the context of the ad-
enovirus genome. We used MCF7 as an example of an ER1
cell line and HeLa as an example of an ER2 cell line. IMR-90
cells are nontransformed human primary fibroblasts from lung
that suffer senescence after a series of passages in culture. We
verified by reverse transcriptase (RT)-PCR that MCF-7 and
HeLa cells express telomerase, whereas IMR-90 cells are neg-
ative (data not shown), as described in the literature (Meyerson
et al., 1997; Majumdar et al., 2001). Cells were infected for 10
hr with an MOI of 20 PFU/cell of either AdEHT2, AdEHE2F,
or AdWT as a control. Cells were maintained in RPMI medium
supplemented with 2% FBS and 2 nM 17b-estradiol, with or
without hypoxia (1% O2). In addition, a set of MCF7 cells was
incubated in the absence of estrogens. Total RNA was extracted
and expression of the E1A and E4 transcription units was an-
alyzed by Northern blot using specific probes, as shown in Fig.
4. There is a tight regulation of the E1A region in both AdEHT2
and AdEHE2F. In all the cell lines tested, hypoxia induced
strong expression of E1A. Importantly, the expression was un-
detectable in the ER2 cell line HeLa under normoxic condi-
tions. In MCF7 cells basal expression was low, estrogens caused
activation, and the best response was obtained by hypoxia and
estrogens together. These data indicate that the minimal
ERE/HRE promoter maintains its properties of low basal ac-
tivity and high inducibility in the context of the adenoviral ge-
nome. The use of an insulator sequence might contribute to the
tight regulation of the E1A region in these viruses. On occa-
sion, cells infected with AdWT showed a slight increase in E1A
expression in response to hypoxia, as is the case for HeLa in
this assay. In fact, analysis of the left arm of the adenovirus ge-
nome reveals some HRE-like sequences. The significance of
this finding is unclear, because the ability of the wild-type virus
to replicate was not significantly increased by hypoxia (see be-
low). Probably the increase in E1A expression above a certain
threshold is irrelevant for its function. In contrast with the high
levels of E1A obtained in cells infected with the recombinant
adenovirus, the expression of the E4 region in both viruses was
relatively low when compared with the wild-type virus. This is
especially true for IMR-90 cells, which lack expression of telo-
merase. However, it is not clear that this is due to specific reg-
ulation of the hTERT or E2F-1 promoter. As can be seen in
HeLa cells infected for 10 hr with AdEHT2 and AdEHE2F, the
expression of E4 is low unless the cells are maintained under
hypoxic conditions. This suggests that the signals controlling
expression of telomerase or the basal levels of E2F in these
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FIG. 4. Transcriptional control of the E1A and E4 units. MCF7, HeLa, and IMR-90 cells were pretreated for 10 hr with 2 nM
17b-estradiol (E) or 2 nM 17b-estradiol plus hypoxia (EH). In addition, one set of MCF7 cells was maintained in estrogen-de-
pleted medium (C). Cells were then infected with an MOI of 20 PFU/cell of AdEHT2, AdEHE2F, or AdWT, under the same
treatment conditions. Ten or 14 hr after infection, total RNA was extracted. Northern blot analysis was performed with radioac-
tive probes specific for the E1A region, E4 region, or the constitutively expressed b-actin gene as a control. The intensity of the
signal should not be compared between different cells because in this short period of time, it reflects mostly the sensitivity of
the cells to adenovirus infection (which is highest in HeLa cells and lowest in IMR-90 cells, as can be deduced from the inten-
sity of the signal obtained in AdWT-infected cells). The times of exposure of the autoradiograms are different for each blot. The
experiment was repeated three times with similar results.
transformed cells are by themselves unable to stimulate E4.
However, under hypoxic conditions the levels of E1A are high
and this appears to cooperate in the activation of the E4 pro-
moter. In the case of AdEHE2F, this may be a consequence of
the sequestration of pRB by E1A. In AdEHT2, a less specific
mechanism could be taking place, because E1A is known as a
ubiquitous activator of transcription in many promoters (Flint
and Shenk, 1997), and that may be happening to the hTERT
promoter as well. To evaluate the regulation of the E4 region
in more detail, we repeated the Northern blot assays 14 hr af-
ter infection, as indicated in Fig. 4. At this time, the influence
of E1A is more evident. In fact, the expression of E4 in MCF7
and HeLa cells infected with the CRADs clearly responds to
the same stimuli (expression of ERs and hypoxia). Although
E4 is still low in IMR-90 cells, a slight increase can be ob-
served under hypoxic conditions, especially in the case of
AdEHE2F. In summary, the activity of the E4 unit driven by
the hTERT and E2F-1 promoters is attenuated in normal cells,
but it can be influenced by the levels of E1A.
Modulation of the cytotoxicity of AdEHT2 and
AdEHE2F by hypoxia
Hypoxia is a strong activator of the E1A region for both
AdEHT2 and AdEHE2F, and this also affects expression of the
E4 region indirectly. We then examined the consequences of
this regulation on the ability of these viruses to replicate and
kill cells in culture. We compared the ER1 cell lines MCF7 and
BT-474, and the ER2 cell lines HeLa and SK-BR-3. Cells were
infected with AdEHT2, AdEHE2F, or AdWT at an MOI of 10
PFU/cell and viability was quantified 9 days after infection, us-
ing the MTT assay (Fig. 5). We chose an MOI that caused no
CPE in the first 3 days postinfection even with the wild-type
virus, to make sure that any effect that appears later on is due
to virus replication. All the cells were incubated in the pres-
ence of 17b-estradiol; some of them under normoxic and some
under hypoxic conditions. In good correlation with the expres-
sion of E1A, both recombinant adenoviruses caused extensive
death of MCF7 cells in the presence of estrogens (90% decrease
in viability), with or without hypoxia. The same was true for
the other ER1 cell line BT-474, with virtually complete eradi-
cation of cells at the end of the experiment. On the other hand,
HeLa cells were not significantly affected under normoxic con-
ditions, which suggests that the expression of ER is necessary
for activation of the viruses in the absence of hypoxia. How-
ever, lowering the oxygen tension to 1% caused significant ac-
tivation of the capacity of the CRADs to kill these cells, with
80% reduction in viability observed with AdEHE2F. In the case
of SK-BR-3, hypoxia stimulates the cytotoxicity of the recom-
binant adenoviruses, but the attenuation under normoxic con-
ditions is only partial, especially for AdEHE2F. Interestingly,
this cell line overexpresses the Her2/neu oncogene (Moulder et
al., 2001), which can cause increased levels of HIF in the ab-
sence of hypoxia (Laughner et al., 2001). Note that the ability
of AdWT to kill cells was not affected by hypoxia. In summary,
hypoxia induced a significant increase in cytotoxicity only for
AdEHT2 and AdEHE2F, and the expression of ERs in the cells
had a permissive role for these viruses. Finally, we performed
a dose–response analysis and calculated the MOI of virus nec-
essary to kill 50% of the cells in order to estimate the extent of
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FIG. 5. Viability of different human cancer cell lines infected with AdEHT2 and AdEHE2F. The ER1 cell lines MCF7 and
BT-474, and the ER2 cell lines HeLa and SK-BR-3, were infected with AdEHT2 (EHT), AdEHE2F (E2F), or AdWT (WT) at
an MOI of 10 PFU/cell in the presence of 2 nM 17b-estradiol. Cells were maintained under normoxic conditions (solid columns)
or hypoxic conditions (hatched columns) for 9 days, and viability was analyzed by the MTT assay. The columns represent the
percentage of surviving cells, compared with uninfected cells growing under the same conditions. The experiment was repeated
five times with similar results.
regulation by hypoxia. In HeLa cells hypoxia can stimulate at
least 10-fold the ability of CRADs to eliminate these cells
(Table 1). In BT-474 cells, the maximum cytotoxicity effect
was always achieved when both estrogens and hypoxia were
present, but the expression of ERs allowed nearly full activity
of the viruses. Overall, AdEHE2F was 3-fold more cytotoxic
than AdEHT2, but it was still attenuated about 5-fold when
compared with the wild-type adenovirus, whose cytotoxicity
was not affected by hypoxia. In summary, these results indicate
that the expression of ERs in the cells, or the existence of a hy-
poxic environment, are key factors that control the prolifera-
tion and cytotoxicity of the new CRADs.
Evaluation of the hTERT and E2F-1 promoters 
in the E4 region of adenovirus
The purpose of placing the E4 region of adenovirus under
the control of the hTERT promoter was to confine the replica-
tion of adenovirus only to cells that express telomerase. North-
ern blot assays showed that the activity of the E4 region of
AdEHT2 seemed to be attenuated in IMR-90 primary cells,
which do not express this enzyme (Fig. 4). However, the acti-
vation of the promoter in HeLa or MCF7 cells was also low,
and it was apparent only when E1A expression was also acti-
vated by hypoxia. Despite the low levels of E4 in MCF7 cells
under normoxic conditions, AdEHT2 was still able to replicate
and kill these cells. The consequences of this situation in terms
of virus replication and cytotoxicity were evaluated in a via-
bility assay using telomerase-negative IMR-90 cells. As shown
in Fig. 6A, when these cells were infected under hypoxic con-
ditions, AdEHT2 was not attenuated. In fact, it showed effects
similar to those of the wild-type virus, suggesting that the in-
fluence of E1A expression activated by hypoxia is sufficient to
allow replication of the virus. When the same experiment was
repeated with AdEHE2F, a more pronounced reduction of cell
viability was observed with hypoxia treatment (Fig. 6B). In this
case the result is not surprising if we consider that in some sit-
uations, E1A can activate the E2F-1 promoter by blocking the
pRB pathway (Flint and Shenk, 1997).
To evaluate the ability of the E2F-1 promoter to attenuate
the replication of adenovirus in quiescent cells, we compared
the viability of IMR-90 cells infected with AdEHE2F in serum-
free medium versus medium that contains 2% FBS. Unlike most
cancer cell lines, these primary cells do not express E2F-1 and
other proliferation-related transcription factors when they are
maintained in serum-free medium, but serum can reactivate
their expression (Good et al., 1996). Figure 7A shows that, as
expected, AdEHE2F was attenuated in quiescent cells. This ef-
fect was not a general characteristic of adenovirus, because it
was not observed with AdWT. Actually, the cells were slightly
more sensitive when infected with this virus in serum-free
medium (Fig. 7B). In addition, the attenuation did not take place
in the breast cancer cell line MCF7 (Fig. 7C). These results sug-
gest that the E2F-1 promoter controlling the E4 region can help
to diminish the replication of adenovirus in normal somatic
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TABLE 1. MODULATION OF CYTOTOXICITY OF
AdEHT2 AND AdEHE2F BY HYPOXIAa
AdEHT2 AdEHE2F AdWT
N H N H N H
BT-474 .102 00.5 00.4 0.2 0.05 0.07
HeLa .100 19.5 60.5 6.5 1.50 1.50
aBT-474 and HeLa cells were infected with the indicated
viruses at different MOIs in the presence of 2 nM 17b-estra-
diol, under normoxic (N) or hypoxic (H) conditions. Ten days
after infection, the viability of the cells was evaluated by the
MTT assay. Shown are the MOIs that caused 50% loss of via-
bility compared with uninfected cells.
FIG. 6. Viability of IMR-90 cells infected with AdEHT2 and AdEHE2F. Telomerase-negative IMR-90 cells were infected with
AdEHT2 (A) or AdEHE2F (B) at different MOIs in the presence of 2 nM 17b-estradiol, under normoxic (open squares) or hypoxic
(solid squares) conditions. As a control, cells were infected with AdWT under hypoxic conditions (discontinuous line). The viabil-
ity of the cells was analyzed 10 days after infection, using the MTT assay. The percentage of viable cells is presented on the y axis
and the MOI in logarithmic scale is presented on the x axis. The experiment was repeated three times with similar results.
cells. To validate this point, we tested four additional non-
transformed human cells: BJ and NHFib are fibroblasts derived
from skin, HDMECs are endothelial cells, and NHK cells are
keratinocytes derived from skin. The cells were infected under
normoxic conditions with either AdEHE2F or AdWT at differ-
ent MOIs. The viability of the cells was analyzed when the
monolayers infected with AdWT showed extensive cytopathic
effect for each cell type. As shown in Fig. 8, the normal cell
populations maintained at least 70% viability when infected
with AdEHE2F, whereas the same amount of AdWT killed vir-
tually all the cells. However, when we performed AdEHE2F
infection under hypoxic conditions, the ability of the virus to
replicate and kill these cells was greatly activated, reaching lev-
els similar to the wild-type version. This suggests that the at-
tenuation of AdEHE2F in normal cells is specific, and is not
simply due to a general reduction of its ability to induce cell
death compared with AdWT.
Toxicity of AdEHE2F in mice
To evaluate whether the specificity observed with AdEHE2F
in cultured cells correlated with a reduction in toxicity in vivo,
we performed intravenous injections of either AdEHE2F,
AdWT, or the E1-deleted adenoviral vector AdDE1. Increasing
amounts of viral particles were injected into the retro-orbital
plexus of Hsd nu/1 mice. We monitored mortality, weight loss,
and damage to liver by quantification of the enzyme alanine
aminotransferase (ALT). The results are summarized in Fig. 9.
We observed that any dose above 1 3 1011 particles of AdWT
causes death of all the mice 4 days after injection, with severe
elevation of ALT levels in the first 48 hr. A dose of 0.6 3 1011
particles induces a moderate increase in ALT, but no deaths or
weight loss occurred. On the other hand, AdEHE2F was well
tolerated at 1 3 1011 particles, with no mortality and no liver
toxicity. This virus was lethal to most of the mice at doses above
4.5 3 1011 particles, whereas 2.2 3 1011 particles caused the
death of only one of four animals. Interestingly, ALT levels in
mice that died after AdEHE2F administration were generally
lower than those observed for AdWT. In fact, most of the mice
died with enzyme levels only twice the upper normal limit
(about 120 U/L). Finally, AdDE1 showed no signs of toxicity
even at the highest dose tested (4.5 3 1011 particles). Only a
slight increase in ALT levels, still within the physiological
range, could be observed. In summary, the toxicity of AdEHE2F
is reduced compared with the wild-type virus, but it is some-
what more toxic than a replication-deficient adenoviral vector.
Antitumor effect in vivo
We evaluated the ability of AdEHT2 and AdEHE2F to in-
hibit the growth of human breast cancer xenografts established
in estrogen-treated nude mice. The tumors were generated by
orthotopic injection of BT-474 cells into the mammary fat pad.
When they reached an average of 200 mm3, 5 3 108 PFU of
virus was injected intratumorally, three consecutive days per
week for a total of four weeks. No side effects related to virus
administration were observed. Variation in the tumor volume
of treated and control mice is shown in Fig. 10. Both AdEHT2
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FIG. 7. Cytotoxicity of AdEHE2F in quiescent cells. (A) IMR-90 cells were infected with different MOIs of AdEHE2F in the
presence of 2 nM 17b-estradiol. The cells were maintained in serum-free medium (open squares), or in the usual infection medium
containing 2% FBS (solid triangles). The viability was analyzed 8 days after infection, using the MTT assay. The percentage of
viable cells is presented on the y axis and the MOI in logarithmic scale is presented on the x axis. The same experiment was per-
formed with the AdWT virus and IMR-90 cells (B), and with AdEHE2F virus and MCF7 cells (C). Note that the MOIs used are
lower in the case of MCF7 cells. For this assay, we infected a higher initial number of IMR-90 cells than in previous viability
assays (2 3 104 versus 5 3 103), because these cells do not proliferate without serum and at the end of the incubation period
they would fall below the detection limit of the MTT assay. Therefore, (A) and (B) cannot be compared quantitatively with (C),
because the same MOIs actually mean more plaque-forming units per volume of infection medium, and this can affect the effi-
ciency of infection. The experiment was repeated three times with similar results.
and AdEHE2F showed similar antitumor effects. The reduction
in tumor size compared with the control group was significant
after the second week of treatment (p , 0.05), and was close
to 90% 2 weeks later. Both viruses completely inhibited the
growth of tumors. The size of untreated tumors increased more
than 4-fold before they reached a plateau, whereas the treated
tumors remained smaller than their original size. However, re-
sidual lesions could be persistently detected in most of the
treated animals.
DISCUSSION
The ability of CRADs to complete the lytic cycle of adeno-
virus makes them a promising platform to develop new viral or
gene therapy strategies against cancer. However, every step of
this cycle is subjected to complex regulation that is still not
fully understood. The degree and time of expression of viral
proteins, as well as their repertoire of interactions with cellular
counterparts, need to be compatible with productive infection.
When E1A and E1B genes of adenovirus are mutated or deleted
to make the replication of the virus tumor specific (type 1
CRADs), its performance can decrease because some basic
functions of the proteins can be affected. On the other hand,
when the promoters for the E1A and E4 genes are replaced by
tumor or tissue-specific promoters (type 2 CRADs), it is diffi-
cult to predict what impact this will have on replication of the
virus. The combination of promoters used in this study can pro-
vide some information about the latter question. Our results sup-
port the notion that a tight regulation of the E1A region is crit-
ical for the control of adenovirus replication. This can be
achieved by using an artificial, minimal promoter that contains
only the response elements required for its function, in this case
the EREs and HREs. This minimizes the possibility that the
promoter can be activated in certain undesirable cell types or
situations that are difficult to test by transient transfections with
reporter plasmids. Both AdEHT2 and AdEHE2F showed a good
activation of E1A expression by hypoxia in different cell lines,
or by estrogens in ER1 cells. This correlated well with increased
cytotoxicity under the same circumstances. In solid tumors, the
activation of viral replication in hypoxic areas can create mul-
tiple sites in which the concentration of the virus is high. This
could cause destruction of surrounding areas of the tumor, even
if they are not hypoxic, until the titers of virus decrease radi-
ally into the normoxic areas. This could happen independently
of the ER status of the tumor. However, in the case of an ER1
tumor, like many breast cancers, replication of these CRADs
would be activated beyond the hypoxic areas. Again, this may
not require that every single cell in the tumor be ER1. In ad-
dition, the use of a promoter activated by HIF can provide tu-
mor specificity by itself, because overexpression of this tran-
scription factor may be associated with the transformed
phenotype of some cancer cells (Bos et al., 2001).
For several reasons, analyzing the function of the promoters
used in the E4 region of these viruses is more complex. First,
both of them contain binding sites for transcription factors
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FIG. 8. Cytotoxicity of AdEHE2F in human nontransformed
primary cells. BJ and NHFib skin fibroblasts, NHK ker-
atinocytes, and human dermal microvascular endothelial cells
(HDMECs) were infected with AdEHE2F (solid columns) and
AdWT (cross-hatched columns) with an MOI of 750 PFU/cell
for LEHFib, 500 PFU/cell for BJ, and 10 PFU/cell for HD-
MECs and NHK cells. In addition, the cells were infected with
the same amount of AdEHE2F and maintained under hypoxic
conditions (hatched columns). Viability was analyzed by MTT
assay, 16 days after infection for BJ cells and 9 days after in-
fection for LEHFib cells, HDMECs, and NHK cells. The
columns represent the percentage of surviving cells, compared
with uninfected cells growing under the same conditions. The
experiment was repeated three times with similar results
FIG. 9. Toxicity of AdEHE2F. Mice (n 5 4 per group) were
injected intravenously with increasing amounts of either AdWT
(left), AdEHE2F (center), or AdDE1 (right). The doses (3 1011
particles) are indicated below each group. Shown are the serum
levels of alanine aminotransferase (ALT) in units per liter for
every animal, analyzed 48 hr after infection. The solid columns
indicate the mean value for each group. Open circles represent
mice that survived 10 days after infection, whereas solid cir-
cles indicate mice that died, usually 4 days after infection. The
discontinuous line indicates the maximum normal value for
ALT (approximately 120 U/L).
whose expression can be activated under different circum-
stances. The core hTERT promoter used in AdEHT2 contains
AP2, E-box, Myc, and Sp1 binding sites (Horikawa et al., 1999;
Takakura et al., 1999; Wick et al., 1999). The E2F-1 promoter
used in AdEHE2F contains MBF-1, Sp1, NF-kB, and E2F bind-
ing sites (Hsiao et al., 1994; Neuman et al., 1994). Second, both
promoters can be potentially stimulated by E1A, either directly
or as a consequence of the activation of the cell cycle. Finally,
although the E4 region is believed to be necessary for efficient
virus replication because the E4-deleted adenoviruses are at-
tenuated, it is possible that low levels of expression of the E4
open reading frames (ORFs) can support replication if the rest
of the transcription units of the virus are activated. A combi-
nation of these facts might explain the observation that the
AdEHT2 virus was not attenuated in the telomerase-negative
IMR-90 cells when they were infected under hypoxic condi-
tions. Similar results were obtained with Saos-2 cells, a human
osteosarcoma cell line that shows low telomerase activity
(Zhang et al., 2000; and data not shown). Although previous
characterization of the hTERT core promoter suggested that it
was able to provide negative regulation in telomerase-negative
cells (Takakura et al., 1999), it is possible that some key si-
lencer is missing in this short fragment. Therefore, we cannot
rule out the possibility that a longer regulatory region could re-
strict replication of the virus.
Although most of the previous considerations also apply to
the E2F-1 promoter, the fact is that we saw attenuation of the
AdEHE2F virus in cells with a low level of E2F activity, such
as nontransformed cells (IMR-90) maintained in serum-free
medium. This could be a useful feature of this CRAD, because
these conditions apply to most somatic cells. The majority of
cells in the connective tissue, for instance, are not hypoxic and
show low levels of E2F transcription factors because they do
not proliferate continuously. Therefore, it might work as a bar-
rier for the proliferation of AdEHE2F. Many cells in a solid tu-
mor such as breast cancer are also quiescent, but if they are in-
fected by AdEHE2F, as long as they are hypoxic or express
ER, the E1A region of the virus will be expressed, and this may
activate the E4 region. Using the modified adenovirus back-
bone that we have constructed, different combinations of pro-
moters can be tested in order to optimize the CRADs. The EREs
can be avoided to prevent possible side effects in normal ER1
tissues; a mutated E1A that does not bind to pRB can be tested
to avoid activation of the E4 region (Johnson et al., 2002); ar-
tificial minimal promoters can be placed in the E4 region to
achieve a genuine second level of regulation, and newly char-
acterized tumor-specific promoters for particular malignancies
can be readily incorporated in the system. The goal in the de-
sign of CRADs is to achieve an optimum balance between at-
tenuation in normal tissues and full cytolytic activity in tumors.
All the measures described above can contribute to achieve this
goal. In the case of AdEHT2 and AdEHE2F, the relatively low
expression of E4 proteins might be the reason why these viruses
are less efficient than wild type. Still, the E2F-1 promoter used
in AdEHE2F contributed to the attenuation of the virus in nor-
mal cells. Combining this promoter with HREs might enhance
the expression of E4 under hypoxic conditions, and increase the
cytotoxicity of the virus without affecting its regulation. Finally,
the new CRADs that we describe here have shown antitumor
activity in vivo. They were able to block the growth of human
tumor xenografts in nude mice, but they were not able to com-
pletely eradicate them in most of the animals. There may be
physical barriers that limit the dissemination of the virus in the
tumor mass. This problem should be addressed in order to en-
hance the oncolytic potential of these agents. AdEHE2F was
well tolerated when administered intratumorally at doses that
achieved a significant antitumor effect. It is less toxic than the
wild-type adenovirus after intravenous administration, in terms
of both mortality and liver toxicity. In fact, most of the mice
that died from high doses of AdEHE2F had only moderate el-
evations of the ALT enzyme. At present, it is not clear if this
reflects the existence of a different dose-limiting target organ.
Despite the tight regulation of E1A expression observed in cell
culture assays, this virus was still more toxic than a conven-
tional E1-deleted, replication-deficient adenoviral vector.
Strategies to achieve targeted infection, combined with the reg-
ulation of viral replication, will be necessary to obtain an opti-
mum balance between safety and efficacy of CRADs.
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NOTE ADDED IN PROOF
During the preparation and evaluation of this manuscript, two
new CRADs using the E2F-1 promoter have been described by
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FIG. 10. Antitumor effect of AdEHT2 and AdEHE2F in vivo.
Human tumor xenografts were established in estrogen-treated
female nude mice by injection of BT-474 cells into the mam-
mary fat pads. Mice were injected intratumorally with either
vehicle alone (solid circles), 5 3 108 PFU of AdEHT2 (open
squares), or 5 3 108 PFU of AdEHE2F (solid triangles) (n 5
5). The treatment was administered for three consecutive days
per week during the first 4 weeks (open arrows), and then the
mice were left untreated. The significance of the differences
observed between control and treated groups was analyzed by
Student p test.
independent groups (Johnson et al., 2002; Tsukuda et al., 2002).
Their results strongly support the use of this promoter to achieve
cancer-specific replication of adenoviruses.
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